NEW YORK (GenomeWeb News) – Beckman Coulter Genomics today said that three states have licensed its BRAF assay, expanding the availability of the test.

Pennsylvania, Maryland, and Rhode Island have granted clinical laboratory licenses to Beckman Coulter Genomics for the assay, which is CLIA certified. Massachusetts licensed the assay last year, and of the seven states that require licensures in addition to CLIA certification for certain tests to be offered there, Florida, California, and New York remain the only ones that have not licensed Beckman Coulter's BRAF assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.